Zydus Lifesciences Statistics

Total Valuation

Zydus Lifesciences has a market cap or net worth of INR 970.81 billion. The enterprise value is 971.07 billion.

Market Cap	970.81B
Enterprise Value	971.07B

Important Dates

The next estimated earnings date is Tuesday, February 4, 2025.

Earnings Date	Feb 4, 2025
Ex-Dividend Date	Jul 26, 2024

Share Statistics

Zydus Lifesciences has 1.01 billion shares outstanding. The number of shares has decreased by -0.31% in one year.

Current Share Class	n/a
Shares Outstanding	1.01B
Shares Change (YoY)	-0.31%
Shares Change (QoQ)	-0.06%
Owned by Insiders (%)	75.08%
Owned by Institutions (%)	14.00%
Float	249.07M

Valuation Ratios

The trailing PE ratio is 22.76 and the forward PE ratio is 21.36. Zydus Lifesciences's PEG ratio is 2.14.

PE Ratio	22.76
Forward PE	21.36
PS Ratio	4.53
PB Ratio	4.45
P/TBV Ratio	7.13
P/FCF Ratio	30.55
P/OCF Ratio	n/a
PEG Ratio	2.14

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.37, with an EV/FCF ratio of 30.55.

EV / Earnings	22.57
EV / Sales	4.52
EV / EBITDA	15.37
EV / EBIT	17.66
EV / FCF	30.55

Financial Position

The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.01.

Current Ratio	2.27
Quick Ratio	1.34
Debt / Equity	0.01
Debt / EBITDA	0.03
Debt / FCF	0.06
Interest Coverage	72.26

Financial Efficiency

Return on equity (ROE) is 19.57% and return on invested capital (ROIC) is 14.80%.

Return on Equity (ROE)	19.57%
Return on Assets (ROA)	11.74%
Return on Capital (ROIC)	14.80%
Revenue Per Employee	7.98M
Profits Per Employee	1.60M
Employee Count	26,921
Asset Turnover	0.75
Inventory Turnover	1.80

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +41.89% in the last 52 weeks. The beta is 0.42, so Zydus Lifesciences's price volatility has been lower than the market average.

Beta (5Y)	0.42
52-Week Price Change	+41.89%
50-Day Moving Average	982.91
200-Day Moving Average	1,054.73
Relative Strength Index (RSI)	44.54
Average Volume (20 Days)	873,612

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Zydus Lifesciences had revenue of INR 214.84 billion and earned 43.03 billion in profits. Earnings per share was 42.65.

Revenue	214.84B
Gross Profit	151.81B
Operating Income	53.83B
Pretax Income	57.58B
Net Income	43.03B
EBITDA	61.86B
EBIT	53.83B
Earnings Per Share (EPS)	42.65

Full Income Statement

Balance Sheet

The company has 24.95 billion in cash and 1.91 billion in debt, giving a net cash position of 23.05 billion or 22.90 per share.

Cash & Cash Equivalents	24.95B
Total Debt	1.91B
Net Cash	23.05B
Net Cash Per Share	22.90
Equity (Book Value)	241.55B
Book Value Per Share	217.00
Working Capital	68.06B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 45.94 billion and capital expenditures -14.16 billion, giving a free cash flow of 31.78 billion.

Operating Cash Flow	45.94B
Capital Expenditures	-14.16B
Free Cash Flow	31.78B
FCF Per Share	31.59

Full Cash Flow Statement

Margins

Gross margin is 70.66%, with operating and profit margins of 25.06% and 20.03%.

Gross Margin	70.66%
Operating Margin	25.06%
Pretax Margin	26.80%
Profit Margin	20.03%
EBITDA Margin	28.79%
EBIT Margin	25.06%
FCF Margin	14.79%

Dividends & Yields

This stock pays an annual dividend of 3.00, which amounts to a dividend yield of 0.31%.

Dividend Per Share	3.00
Dividend Yield	0.31%
Dividend Growth (YoY)	-50.00%
Years of Dividend Growth	1
Payout Ratio	7.05%
Buyback Yield	0.31%
Shareholder Yield	0.62%
Earnings Yield	4.42%
FCF Yield	3.27%

Dividend Details

Stock Splits

The last stock split was on October 6, 2015. It was a forward split with a ratio of 5.

Last Split Date	Oct 6, 2015
Split Type	Forward
Split Ratio	5

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a